3-aminopyridine-1,n(6)-ethenoadenine dinucleotide phosphate has been researched along with Myelodysplastic Syndromes in 1 studies
*Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, A; Fradin, Z; Mittelman, M; Redlich, O; Sokolover, N; Zeidman, A | 1 |
1 other study(ies) available for 3-aminopyridine-1,n(6)-ethenoadenine dinucleotide phosphate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Platelet function and its clinical significance in the myelodysplastic syndromes.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Blood Platelets; Collagen; Epinephrine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Aggregation; Prognosis; Ristocetin | 2004 |